Background:The microbiological ecosystem is considered the main obstacle in endodontics. Therefore, canal disinfection became a great priority. Aim of the study:This study was established to assess cysteamine's antibacterial effect against E. Faecalis and compare the improvement effect to its combination with various intracanal medicaments. Methods and Materials:Cleaning and shaping were performed on human single-rooted teeth then inoculated by E. faecalis biofilm. Samples were divided randomly into three groups: Group I to verify the maturation of E. faecalis biofilm inside the root canal using SEM. Group II were divided into four subgroups according to the intracanal medication used. Subgroup A was treated with Cysteamine. Subgroup B was treated with Chlorhexidine Cysteamine combination. Subgroup C was treated with Calcium hydroxide (CaOH) Cysteamine combination. Subgroup D was treated with Triple antibiotic paste Cysteamine combination. Group III were divided into two subgroups treated with plain gel: positive control and negative control. Samples collected from root canals were used for viable count (CFU/ml). Log transformation of the data was carried out. The statistical significance level was set at P < 0.05. Results:There was a significant difference between different groups (p<0.001). Post hoc pairwise comparisons showed statistically significant difference between subgroups except for the CaOH Cysteamine combination subgroup and TAP Cysteamine combination subgroup. Conclusion:Cysteamine usage provides a synergistic antibacterial effect with other intracanal medications. CHX Cysteamine combination was the most effective antibacterial drug that provided effectiveness against E. faecalis.
Objective: This study was established to assess cysteamine’s cytotoxic effect alone and in combination with various intracanal medications on fibroblast cells. Because the biocompatibility of intracanal medication is considered one of the main factors that affect the selection of specific medication for usage near vital periodontal tissues. Materials and Methods: All tested medications were prepared in a solution form. Cysteamine preparation was prepared at 200mg/ml concentration in distilled water. Chlorhexidine Cysteamine combination was prepared by dissolving 10 mg/ml of Cysteamine in CHX. Calcium hydroxide Cysteamine combination was prepared by dissolving 10 mg/mL of Cysteamine in a saturated solution of CaOH. TAP Cysteamine combination was prepared by dissolving 10 mg/mL of Cysteamine in TAP. BHK cells were seeded in well-microtiter plates. The testing materials were filtrated using a 0.22 μm syringe filter. BHK-21 cells precultured well plates were treated with descending 12-fold serially diluted medications at 37 °C for 24 h. Residual living cells were treated with 25 μl of MTT dye. MTT was discarded, then Dimethyl sulfoxide was added as 50 μl/well. The absorbance was conducted at 570nm. The mean optical density and 50 % cell growth inhibition (IC50) were calculated. The significance level was set at p≤0.05. Results: Viability % and IC50 results showed that TAP Cysteamine combination had the lowest cytotoxicity level compared to other intracanal combinations followed by Cysteamine and the highest cytotoxicity was with Chlorhexidine Cysteamine combination. Conclusion: TAP Cysteamine combination was the safest drug compared to other drug combinations with cysteamine, so it needs more research to detect its acceptance with stem cells and its effect on defense mechanisms during healing.
Background This study was established to assess cysteamine’s cytotoxic effect alone and in combination with various intracanal medications on fibroblast cells, because the biocompatibility of intracanal medication is considered one of the main factors that affect the selection of specific medication for usage near vital periodontal tissues. Methods All tested medications were prepared in a solution form. Cysteamine preparation was prepared at 200 mg/ml concentration in distilled water. The chlorhexidine–cysteamine combination was prepared by dissolving 10 mg/ml of cysteamine in chlorhexidine. Calcium hydroxide–cysteamine combination was prepared by dissolving 10 mg/mL of cysteamine in a saturated solution of calcium hydroxide (CaOH). Triple antibiotic paste (TAP)–cysteamine combination was prepared by dissolving 10 mg/mL of cysteamine in triple antibiotic paste (TAP). BHK cells were seeded in well-microtiter plates. The testing materials were filtrated using a 0.22 μm syringe filter. BHK-21 cells precultured well plates were treated with descending 12-fold serially diluted medications at 37 °C for 24 h. Residual living cells were treated with 25 μl of MTT dye. MTT was discarded, and then, dimethyl sulfoxide was added as 50 μl/well. The absorbance was conducted at 570 nm. The mean optical density and 50% cell growth inhibition (IC50) were calculated. Cell viability data showed parametric distribution, so they were analyzed using one-way ANOVA followed by Tukey’s post hoc test for intergroup comparisons and repeated measures ANOVA followed by Bonferroni’s post hoc test for intragroup comparisons. The significance level was set at p ≤ 0.05. Results Viability % and IC50 results showed that triple antibiotic paste (TAP)–cysteamine combination had the lowest cytotoxicity level compared to other intracanal combinations followed by cysteamine and the highest cytotoxicity was with chlorhexidine–cysteamine combination. Conclusions Triple antibiotic paste (TAP)–cysteamine combination was the safest drug compared to other drug combinations with cysteamine, so it needs more research to detect its acceptance with stem cells and its effect on defense mechanisms during healing.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.